Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

PHASE3RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2027

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

NRT6003 Injection

Patients will be administered NRT6003 Injection via Intra-arterial infusion, and subsequently they will be assessed by PET/CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.

DRUG

cTACE

Patients will receive cTACE treatment. And the investigators will select one or more chemotherapy drugs in combination with embolic materials for administration, based on the specific condition of the patient.

Trial Locations (11)

210009

RECRUITING

Zhongda Hospital Southeast University, Nanjing

Unknown

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

RECRUITING

The First Hospital of China Medical University, Shenyang

RECRUITING

West China Hospital, Chengdu

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Chengdu New Radiomedicine Technology Co. LTD.

INDUSTRY